Background: The goal of this study was to evaluate whether the medical recommendation of Angocin^®Anti-Infekt N (heretofore referenced as Angocin^®) on the day of diagnosis of acute bronchitis is negatively associated with the recurrence of acute bronchitis diagnosis, antibiotic prescriptions, incidence of chronic bronchitis, and duration of sick leave. Methods: This study included patients in general practices in Germany with a first documented diagnosis of acute bronchitis between 2005 and 2022 (index date) and a prescription of Angocin^®, thyme products, essential oils, mucolytics or antibiotics on the index date. The association between Angocin^® prescription and the risks of a relapse of acute bronchitis, development of chronic bronchitis, or subsequent antibiotic prescription were evaluated using Cox regression models. Univariable conditional logistic regression models were used to investigate the association between Angocin^® prescription and duration of sick leave. Results: After a 1:5 propensity score matching, 598 Angocin^® patients and 2990 patients in each of the four comparison cohorts were available for analysis. Angocin^® prescription was associated with significantly lower incidence of a renewed confirmed diagnosis of acute bronchitis as compared to essential oils (Hazard ratio (HR): 0.61; 95% Confidence Interval (CI): 0.46–0.80), thyme products (HR: 0.70; 95% CI: 0.53–0.91), mucolytics (HR: 0.65; 95% CI: 0.49–0.85) or antibiotics (HR: 0.64; 95% CI: 0.49–0.84). Also, there were significantly lower incidences of subsequent re-prescriptions of antibiotics when compared to mucolytics (HR: 0.73; 95% CI: 0.53–0.99) or antibiotics (HR: 0.53; 95% CI: 0.39–0.72) and a significantly lower risk of chronic bronchitis as compared to essential oils (HR: 0.60; 95% CI: 0.46–0.78), thyme products (HR: 0.53; 95% CI: 0.41–0.69), mucolytics (HR: 0.49; 95% CI: 0.38–0.63) or antibiotics (HR: 0.59; 95% CI: 0.45–0.76). Conclusions: Considering the limitations of the study, the results shed light on the sustaining effectiveness of Angocin^® prescription in the management of acute bronchitis and the associated outcomes when compared to several other treatments commonly used for this condition.

Background: The goal of this study was to evaluate whether the medical recommendation of Angocin^® Anti-Infekt N, compared to standard antibiotic treatment shortly after the diagnosis of a urinary tract infection (UTI) or cystitis, is negatively associated with an early, sporadic, or recurrent UTI, subsequent antibiotic prescriptions, pyelonephritis as a renal complication, or UTI-associated sick leave. Methods: This retrospective cohort study was based on data from the IQVIA^TM Disease Analyzer database and included patients diagnosed with acute UTI or cystitis by physicians in Germany between 2005 and 2021, who were prescribed either Angocin^® or standard antibiotics within 4 days after diagnosis. Patients prescribed antibiotics were matched to those prescribed Angocin^® (5:1) using propensity scores. Univariable logistic and Cox regression models were used to investigate the association between Angocin^® prescription and the defined study outcomes. The effects of Angocin^® were adjusted for age, sex, insurance status, index diagnosis, and physician specialty. Results: A total of 2277 Angocin^® patients and 11,385 antibiotic patients were available for analysis. Compared to antibiotic prescriptions, Angocin^® prescription was associated with significantly lower odds of an early relapse within 1–30 days after the index date (odds ratio (OR): 0.74; 95% confidence interval (CI): 0.62–0.87; p < 0.001), further sporadic UTI within 31–365 days after the index date (OR: 0.68; 95% CI: 0.58–0.78; p < 0.001), and recurrent UTI (OR: 0.63; 95% CI: 0.48–0.82; p < 0.001). This was also accompanied by reduced antibiotic prescriptions (1–30 days: OR: 0.63; 95% CI: 0.53–0.74, p < 0.001; 31–365 days: OR: 0.56; 95% CI: 0.49–0.64, p < 0.001). A strong, but due to the low incidence, not significant, negative association was observed between Angocin^® prescription and the occurrence of pyelonephritis (hazard ratio (HR): 0.67; 95% CI: 0.43–1.06; p = 0.073). Conclusions: The results of this real-world data study demonstrate that Angocin^® can be an effective therapeutic option for managing acute and recurrent UTIs and serves as an alternative therapy to antibiotics.

Background: The goal of this study was to evaluate whether medical recommendation of Angocin^® Anti-Infekt N (hereafter referred to as Angocin^®) on the day of diagnosis of an acute upper respiratory tract infection (aURTI) or acute sinusitis (AS) is negatively associated with a recurrence of these diagnoses, incidence of antibiotic prescriptions, incidence of chronic sinusitis, nasal polyps, or sick leave duration. Methods: This retrospective cohort study utilized the IQVIA^TM Disease Analyzer database and included patients by general practitioners with at least one diagnosis of aURTI or AS from 2005 to 2024 and a prescription of Angocin^®, nasal medications (xylometazoline, oxymetazoline) and mucolytics (ambroxol or acetylcysteine), other phytopharmaceutical drugs, or antibiotics on the day of diagnosis. Patients who received Angocin^® were matched separately to each of the three comparison cohorts in a 1:5 ratio using a nearest-neighbor propensity score approach. The relationship between Angocin^® prescription and the risks of a recurrence, subsequent antibiotic use or progression to chronic disease was then estimated with Cox proportional hazard models. To examine whether Angocin^® exposure was associated with the length of sick leave, univariable conditional logistic regression was applied. Results: A total of 3501 Angocin^® patients and 17,505 patients in each further cohort were investigated. Angocin^® prescription was associated with a significantly lower incidence of a newly diagnosed aURTI/AS as compared to other phytopharmaceuticals (Hazard ratio (HR): 0.78; 95% confidence interval (CI): 0.68–0.86), nasal medications and mucolytics (HR: 0.79; 95% CI: 0.71–0.88), or antibiotics (HR: 0.85; 95% CI: 0.77–0.95). In addition, there was a significantly lower incidence of subsequent further prescriptions of antibiotics when compared to other phytopharmaceuticals (HR: 0.92; 95% CI: 0.82–0.99), nasal medications and mucolytics (HR: 0.87 (95%; CI: 0.80–0.95), or antibiotics (HR: 0.62; 95% CI: 0.57–0.67). Furthermore, Angocin^® was associated with the most advantageous pattern of work absence across all time periods examined. Conclusions: Considering the limitations of the study, the results cast a positive light on Angocin^® prescription in the management of aURTI/AS, particularly with regard to recurrence rates, subsequent antibiotic prescriptions, and sick leave duration.